Work

A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.4559

Authors: Rana R. McKay, Lillian Werner, Lauren Christine Harshman, Joaquim Bellmunt, Christopher Sweeney, Jonathan E. Rosenberg, Eliezer VanAllen, Meghara K. Walsh, Ulka N. Vaishampayan, David F. McDermott, Toni K. Choueiri

Institutions: Harvard University, Dana-Farber Cancer Institute, Stanford Medicine, Stanford University, Memorial Sloan Kettering Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Beth Israel Deaconess Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2592003962

Cites:

Cited by: 2

Related to: 10